G Protein–Coupled Receptor Kinase 5
Exploring Its Hype in Cardiac Hypertrophy

Stephen L. Belmonte, Burns C. Blaxall

It is an established dogma that G-protein–coupled receptor kinases (GRKs) classically direct the desensitization and internalization of their eponymous receptors through direct phosphorylation. Yet, it is the noncanonical action of GRKs that has increasingly attracted the interest of groups seeking novel insight into vexing pathophysiological questions. Among the 7 GRK isoforms, several findings suggest that GRK5 may have particular relevance to the development of cardiac hypertrophy and heart failure (HF). Beyond its classical function, GRK5 contains a DNA-binding nuclear localization sequence and has recently been reported to modify myocardial gene transcription through histone deacetylase activity. Furthermore, GRK5 expression is elevated in the ventricles of patients with HF and transgenic cardiac-specific GRK5 overexpression produced pronounced hypertrophy and accelerated HF progression upon pressure-overload challenge in mice.

In evaluating the results presented in the article by Gold et al., it becomes apparent that GRK5 may represent a viable therapeutic target for the treatment of HF, for which new therapies are desperately needed. As with most new and exciting discoveries, there are various facets of GRK5 biology to consider before clinical application. For example, it was previously reported that the global GRK5 knockout mouse exhibits enhanced muscarinic receptor sensitivity but no gross anatomical differences from wild-type littermates. In addition, a recent study found high expression of GRK5 in white adipose tissue, underlying reduced adipogenesis and obesity in GRK5-null animals. Thus, while cardiac functional parameters clearly suggest a protective role of GRK5 in the heart, it would also be valuable to assess ratios of heart weight to tibia length in addition to body weight, as well as to quantify myocyte size. It is interesting to note that both global and cardiac-restricted GRK5 knockout mice demonstrated progressive, mild (possibly compensatory) cardiac hypertrophy after transverse aortic constriction, whereas the wild-type mice followed the more traditional progression of concentric hypertrophy followed by rapidly decompensated, eccentric hypertrophy coupled to ventricular wall thinning. Attenuation of the hypertrophic gene expression profile after myocardial insult in GRK5 knockouts, partially explained by modest but significant alterations in non-nuclear histone deacetylase phosphorylation, further validates an important role for GRK5 in pathological cardiac hypertrophy.

Importantly, GRK5 is expressed in multiple cardiac cell types. In their current article, Gold et al. report relatively similar results in both the global and cardiomyocyte-restricted GRK5 mice. Future investigation will be needed to determine the possible functional relevance of GRK5 in the maladaptive hypertrophic response in various nonmyocyte cardiac cells (eg, fibroblasts). Interestingly, prior studies have documented divergent effects of altered GRK5 expression/activity. For example, hybrid transgenic mice overexpressing cardiac GRK5 and a constitutively active α1B-adrenergic receptor mutant demonstrated that GRK5 reduced α1B-adrenergic receptor hypertrophy and partially reduced atrial natriuretic factor mRNA. Although somewhat inconsistent with the current report, the inherent differences in the mechanism of injury induced by an activated mutant receptor, transverse aortic constriction, and persistent agonist stimulation may, in large part, explain the discrepancy. It is known that GRK5 phosphorylates and desensitizes α1B-adrenergic receptor basally but not after agonist stimulation. Furthermore, the α1B-adrenergic receptor is preferentially expressed in cardiac fibroblasts, whereas the α1A subtype predominates in myocytes. It is also likely that GRK5 overexpression confers protection via enhanced desensitization.

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester Medical Center, Rochester, NY (S.L.B., B.C.B.), and The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH (B.C.B.).

Correspondence to Burns C. Blaxall, The Heart Institute, Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, MLC 7020, Cincinnati, OH 45229-3039. E-mail burns.blaxall@cchmc.org


Circulation Research is available at http://circres.ahajournals.org

DOI: 10.1161/CIRCRESAHA.112.278432

957
of β-adrenergic receptors, as observed previously in mice.\textsuperscript{10} This is also the putative explanation for the improved outcomes of patients with HF with a highly active GRK5 polymorphism.\textsuperscript{11} Considering that GRK5 exhibits differential receptor subtype specificity and has both nuclear and membrane receptor kinase activity, further work is required to establish a definitive role for GRK5 in maladaptive cardiac hypertrophy in a variety of cardiac cell types.

One final point to address is how GRK5 regulates gene transcription. Hypertrophic gene expression is primarily considered in terms of upregulated genes, but downregulated genes are also clinically relevant to hypertrophy and HF. Indeed, it was recently reported that in mice overexpressing Gαq, which produces a pressure-overload cardiac HF. Indeed, it was recently reported that in mice overexpressed genes are also clinically relevant to hypertrophy and considered in terms of upregulated genes, but downregulated transcription. Hypertrophic gene expression is primarily hypertrophy in a variety of cardiac cell types.

In summary, GRK5 expression is clearly pertinent to maladaptive cardiac hypertrophy and the development of HF. Further advances in our understanding of the functional role of GRK5 in heart failure, including those reported by Gold et al,\textsuperscript{4} may serve to clarify some inconsistencies and take the quest for a new HF therapeutic yet one step closer to reality.

Sources of Funding

This work was supported by National Institutes of Health Postdoctoral Fellowship ST32ES007026 (S.L.B.) and R01-HL89885 and R01-HL091475 (B.C.B.).

Disclosures

None.

References


Key Words: cardiac hypertrophy \(\n\) G protein-coupled receptor kinase
G Protein–Coupled Receptor Kinase 5: Exploring Its Hype in Cardiac Hypertrophy
Stephen L. Belmonte and Burns C. Blaxall

doi: 10.1161/CIRCRESAHA.112.278432
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/111/8/957

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/